

## Corrections

**Correction in the Article by Kirchhof et al. “2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS”. Rev Esp Cardiol. 2017;70:50.e1-e84**



**Corrección en el artículo de Kirchhof et al. «Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS». Rev Esp Cardiol. 2017;70:50.e1-e84**

The European Society of Cardiology reports the following corrections in the article by Kirchhof et al., “2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS” (Eur Heart J. 2016;37:2893–2962), whose translation, “Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS”, was published in *Rev Esp Cardiol.* 2017;70:50.e1-e84.

Table 15, row Esmolol, column *Control agudo de la frecuencia cardiaca vía intravenosa* (Acute intravenous rate control), “0.5 mg intravenous bolus” should be “0.5 mg/kg intravenous bolus”.

Table 17, in the rows *Dronedarona*, *Fleicanida*, and *d,l-sotalol* (Dronedarone, Flecainide, and d,l sotalol), column *Contraindicaciones principales y precauciones* (Main contra-indications and precautions), the creatinine clearance units are given as ml/dl and ml/ml when the correct unit is ml/min.

These corrections were introduced in the electronic version of the article on 8th August, 2017.